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Abstract. Diabetes Melitus (DM) can cause complications, such as pulmonary tuberculosis 
(TB). Metabolic disorders are thought to be related to Tumor Necrosis Factor-α (TNF-α) 
metabolism, adipocytokines secreted by macrophages, which inhibit insulin transduction, 
has anti-mycobacterial activity, however, also negatively affect pathological TB process. 
This study aims to determine differences in TNF-α levels and Body Mass Index (BMI) in 
DM with pulmonary TB after intensive phase of antituberculosis treatment. This 
prospective comparative analytical study with one-group pretest-posttest design, conducted 
during August 2019-September 2019 in outpatient of Type 2 DM with pulmonary TB at 
USU Hospital, Madani Medan Hospital, Teladan Health Center and Laboratory of Haji 
Adam Malik Medan after approval from the Health Research Ethics Commission. Data 
were analyzed after normality test, then mean difference and correlation test by using the 
SPPS program where p <0.05 was considered significant. This study showed an increase 
BMI, and decrease of fasting blood glucose, 2-hour post-prandial blood glucose, HbA1C 
and TNFα levels before and after intensive phase of antituberculosis treatment (p = 0.001; p 
= 0.001; p = 0.001; p = 0.001).  There was a significant increase of BMI and decrease of 
TNFα level after intensive phase of antituberculosis treatment. 
Keyword: T2DM, Lung Tuberculosis, Antituberculosis treatment, Tumor Necrosis Factor 
α 
Abstrak. Diabetes Melitus (DM) dapat menimbulkan berbagai macam komplikasi, salah 
satunya Tuberkulosis (TB) paru. Gangguan metabolik diduga berkaitan dengan 
metabolisme Tumor Necrosis Factor-α (TNF-α), adipositokin yang disekresikan makrofag 
yang dapat menghambat transduksi insulin, diketahui memiliki aktivitas anti-mikrobakteri, 
dan berdampak negatif dalam proses patologis TB. Penelitian ini bertujuan mengetahui 
perbedaan kadar TNF-α dan Indeks Massa Tubuh (IMT) pasien DM dengan TB paru 
setelah fase intensif pengobatan TB. Penelitian prospektif one group pretest-posttest ini 
bersifat analitik komparatif, dilaksanakan dari bulan Agustus 2019-September 2019 pada 
penderita DM Tipe 2 dengan TB paru di poliklinik rawat jalan RS USU, RS Madani 
Medan, Puskesmas Teladan serta Laboratorium RSUP Haji Adam Malik Medan setelah 
mendapat persetujuan Komisi Etik Penelitian Bidang Kesehatan. Data dianalisis setelah 
uji distribusi, kemudian dilakukan uji beda mean dan uji korelasi menggunakan program 
SPPS di mana p<0,05 dianggap signifikan. Penelitian ini menunjukkan adanya 
peningkatan nilai IMT, serta penurunan kadar GDP, GD2PP, HbA1C dan TNFα yang 
signifikan antara sebelum dan setelah fase intensif pengobatan TB (p = 0,001; p = 0,001; p 
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= 0,001; p = 0,001). Terjadi peningkatan IMT dan penurunan kadar TNFα yang signifikan 
setelah 2 bulan pengobatan dengan OAT. 
Kata Kunci: DM Tipe 2, Tuberkulosis Paru, Obat Antituberkulosis, Tumor Necrosis 
Factor-α 
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1 Introduction 
There is an increase prevalence of Diabetes mellitus (DM) worldwide. The number of DM 
patients in the world was around 415 million, and estimated to be increased about 642 million in 
2040 [1]. DM can cause a variety of complications, one of which is pulmonary tuberculosis 
(TB). This was increase of TB cases in patients with DM, especially in the area of epidemic of 
DM and TB such as China, India and Indonesia. The prevalence of the pulmonary TB in DM 
increased 20 times higher, compared to the prevalence of pulmonary TB in non-DM patients. A 
study reported that the prevalence of TB patients in Indonesia was 12.8% – 42% [2].  
World Health Organization (WHO) states that in 2014, there were 9.6 million pulmonary 
tuberculosis patients all around the world and Indonesia was the second highest prevalence to 
the largest pulmonary tuberculosis case after India [3]. The progress of pulmonary tuberculosis 
disease in DM patients tends to be severe and chronic [2][4]. One of the risk factors of DM 
Type 2 Diabetes Mellitus (T2DM) is excess weight, but diabetic patients tend to undergo weight 
loss along with disease progress. Pulmonary tuberculosis is a chronic disease that also 
contributes to the symptoms of weight loss [5]. 
Metabolic disorders such as obesity and insulin resistance are suspected to have related to the 
metabolism of TNF-α. Several studies had shown the relationship between TNF-α, obesity and 
T2DM [6].  According to previous studies, TNF-α was involved in the pathogensis of insulin 
resistance which affects the incidence of Type 2 Diabetes Melitus and the progression of this 
disease. However, the role of TNF-α in the progression of DM remains unclear [7].  
TNF-α is an adipocytokine that is involved in systemic inflammation and stimulates the acute 
phase of immune reaction. TNF-α is mainly secreted by macrophages, and also by various other 
cells including adipocytes. TNF-α inhibits the transduction of insulin, and has an effect on 
glucose metabolism, so TNF-α can affect the onset and progression of [7]. In addition, TNF-α 
has antimicrobial activity by stimulating the formation of granulomas in tuberculosis patients 
[8]. The recruitment of inflammatory cells in the lung infection process by TB also increased the 
production of TNF-α cytokines, which helped determine the process of forming granulomas in 
patients. Until now, there is still no previous studies on the changes of the TNF-α levels in 
T2DM patients with pulmonary tuberculosis after anti-tuberculosis treatment. Therefore, the 
author wants to know the differences in the TNF-α levels and body mass index (BMI) in T2DM 
patients with pulmonary tuberculosis after intensive phase of anti-tuberculosis treatment. 
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2 Methods 
This is a comparative analytical research with a prospective approach. This one group Pretest-
posttest study, aims to determine the difference of TNF-α levels and body mass index in T2DM 
patients with pulmonary tuberculosis after intensive phase of anti-tuberculosis treatment. This 
study was held in August 2019-September 2019 and patients with DM type 2 and pulmonary 
TB were the outpatient clinic of USU Hospital, Madani Medan Hospital, Teladan Health Center 
and specimen were examined in the Laboratory of RSUP Haji Adam Malik Medan after 
receiving approval from the Health and Research Ethics Commission. Data was analyzed after 
the distribution test, and continued by conducting the mean test and correlation test using SPPS 
program, which p < 0.05 is considered significant. 
3 Results 
Table 1 below showed the characteristics of respondents in this study. There were 25 
respondents, 19 (76%) were male, and 6 (24%) were female, with a mean value of age of 52.6 
years old. 
Tabel 1. Characteristics of Respondents 
Variables 
n = 25 
X±SD 
Gender  
Male, n (%) 19 (76) 
Female, n (%) 6 (24) 
Age (year) 52.6 ± 6.39 
Hemoglobin (g/dL) 11.27 ± 0.96 
Leukocyte (/103mm3)  8.87± 2.95 
Platelets (/103mm3)  341.72 ± 112.21 
BMI (kg/m2) 21.35 ± 1.33 
FBG (g/dL) 193.92 ± 50.78 
2-hr PP Blood Glucose (g/dL)  269.36 ± 80.11 
HbA1C (g%) 9.40 ± 0.96 
TNFα (pg/mL)  503.87 ± 77.02 
                                      BMI : body mass index; FBG : fasting blood glucose; 2-hr PP blood glucose : 2-hour post-       
                                      prandial blood glucose; HbA1C : glycylated hemoglobin; TNFα : tumor necrosis factor alpha 
 
This study showed an increase of mean value of BMI value, as well as a significant decrease of 
mean fasting blood glucose, 2-hour post-prandial blood glucose, HbA1C and TNFα levels 
before and after intensive phase of antituberculosis treatment (p = 0.001; p = 0.001; p = 0,001; p 
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Table 2. Comparison of Anthropometry and Laboratory Parameters Before and After 









BMI (kg/m2) 21.35 ± 1.33 22.16 ± 1.16 0.001 
FBG (g/dL) 193.92 ± 50.78 114.2 ± 18.35 0.001 
2-hr PP Blood Glucose (g/dL) 269.36 ± 80.11 181.64 ± 23.54 0.001 
HbA1C (g%) 9.40 ± 0.96 8.66 ± 0.91 0.001 
TNFα (pg/mL) 503.87 ± 77.02 344.70 ± 57.69 0.001 
BMI : body mass index; FBG : fasting blood glucose; 2-hr PP blood glucose : 2-hour post-prandial blood glucose; 
HbA1C : glycylated hemoglobin; TNFα : tumor necrosis factor alpha 
 
Table 3. Correlation Test of Variables of Risk Factors and TNFα Before and After 
Intensive Phase of Antituberculosis Treatment 
Variabel r p 
BMI (kg/m2) 0.880 0.001 
FBG (g/dL) -0.292 0.157 
2-hr PP Blood Glucose (g/dL) -0.032 0.530 
HbA1C (g%)  0.827 0.001 
TNFα (pg/mL) 0.791 0.001 
                                       BMI : body mass index; FBG : fasting blood glucose; 2-hr PP blood glucose : 2-hour post- 
                                       prandial blood glucose; HbA1C : glycylated hemoglobin; TNFα : tumor necrosis factor alpha 
 
Correlation test showed that the BMI, HbA1C and TNFα levels after intensive phase of 
antituberculosis treatment have a significant relationship and are positively correlated (r = 
0.880; r = 0.827; r = 0.791). This means that the higher the BMI, HbA1C and TNFα level before 
intensive phase of antituberculosis treatment, the BMI, HbA1C and TNFα levels will be higher 
also after intensive phase of antituberculosis treatment. The correlation test results also indicate 
that in this study, although there was a negative correlation of fasting blood glucose and 2-hour 
post prandial blood glucose levels, they had no significant relationship (r =-0.292; r = 0-,032) 
[Table 3]. 
4. Discussion 
In this study, there were differences in the average value of body mass index in TB patients who 
had undergone OAT treatment for intensive phase (p = 0.001). Some previous studies have tried 
to determine the linkage between the differences in weight in conjunction with the treatment of 
antituberculosis. Similar to the results of this study, Chung-Delgado, et.al [9] stated that there 
was a significant weight increase in TB patients undergoing OAT treatment (p < 0.001). Phan, 
et.al. [10] in his study, expressed that, most his respondents (52.6%) experienced an increase in 
body weight in the intensive phase after the antituberculosis treatment, but only 38.4% of the 
groups that experienced the weight gain, were finally gaining weight in the overall treatment 
regimen (p < 0.001). Bernabe-Ortiz, et.al. in [11] expressed the similar results, where there was 
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a significant weight gain when conducting research with a sample of TB patients undergoing a 
given treatment regimen and having a good outcome (p < 0.001) although some of them were 
experiencing weight loss especially in groups with poor outcomes (p < 0.003). Hoa, Lauritsen 
and Rieder [12] specifically found significant weight increase especially occurring within the 
intensive phase of post antituberculosis treatment.   
The mechanism of decline and increase in weight in TB cases remains unclear. Although with 
increased intake of calories and macronutrients, TB infection can still lead to a decrease in fat 
and non-fat mass [13]. The difference in the results can be obscured by the factors of the disease 
itself such as the severity of the disease, smear results, as well as the initial weight when the 
treatment started. Severe malnourishment in the early course of treatment showed a significant 
increase in body weight when there was adequate nutrients given. The decrease of the bacillary 
load occurs mainly in the intensive phase, where it allows the body to re-fill the fat deposits. 
Mycobacterium tuberculosis (MTB) has a reciprocal relationship with blood sugar control. 
According to Segura-Cerda, et.al.[14], high levels of blood sugar cause a defect in immunity to 
MTB infection. Almeida-Junior, et.al. [15] states that there was a correlation between lung 
damage caused by MTB in patients with T2DM. The hyperglycemic state has direct effect on 
the role of macrophages which was the first line in the mechanism against MTB infection. Niazi 
and Kalra [16] showed a decrease in the levels of Th1, cytokines, TNFα, IL-1 and IL-6 levels in 
diabetic patients, compared to non-diabetic patient. Such decline leads to an impaired control 
and inhibition of MTB, mainly due to a decrease in the number of the T cell lymphocytes, and 
impaired macrophage function along with the production of reactive oxidative stress and the 
impaired function of phagocytosis and chemotaxis. Montoya-Rosales, et.al. [17] found a 
negative correlation between glucose concentration and MTB phagocytosis process. Studies 
showed that there were a decline in expression of CD86, CD80 and HLA-DR (molecules that 
had a role in the activation of antigen presentations and Th cell response), which may reduce the 
levels of IL-6 cytokines, IL-1 β, IL-10 and IL-12.   
There were several mechanisms which MTB can lead to hyperglycemic state, such as, stress due 
to infectious diseases may increase cortisol hormone production, which in turn can increase the 
blood sugar levels. In addition, also the release of various cytokine compounds, chemokines and 
tuberculosis proteins may cause pancreatic dysfunction or known as "concomitant pancreatitis". 
This dysfunction led to an increase of amylin deposition in the pancreas due to the increase of 
the function of beta cells due to transient hyperglycemic state. This may lead to the MTB germ 
invasion of the pancreas [18]. 
In this study, control of blood sugar was determined by the examination of fasting blood 
glucose levels, 2-hour post-prandial blood glucose and HbA1C levels, in which in this study, 
were found decrease significantly (p = 0.001; p = 0.001; p = 0.001). Research by Gurukartick, 
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et.al. [19] stated that there was an increase in the number of TB patients with DM which has a 
controlled blood sugar level, as well as a decrease in the number of TB patients with DM that 
did not have uncontrolled sugar levels. Although there were some numbers of samples in his 
research lost, but the test of blood sugar levels from before, after intensive phase and after the 
advanced phase, showed that there was an increasing number of patients who have a controlled 
sugar level, as well as a decrease in the number of patients who have uncontrolled sugar levels 
[19]. Krishnappa, et.al. [18] found 65.4% of the samples were converted to euglycemic status in 
his research on TB patients with T2DM. Through an adequate antituberculosis treatment, 
especially in the intensive phase, by suppressing the amount of MTB in turn can contribute to 
the control of blood sugar. 
TNF-α is an adipocytokine that is involved in acute-phase of systemic inflammatory reactions, 
which is mainly secreted by macrophages, but also by various other cells including adipocytes. 
In relation to T2DM, TNF-α may inhibit insulin transduction, which affects glucose 
metabolism. TNF-α is known to play a role in the onset and development of diabetes mellitus 
type 2 [7]. In relation to the MTB infection, TNF-α has two opposite roles in MTB infection, as 
the resulting cytokines have the simultaneous potential to assist and inhibit the immune 
response to MTB [8]. TNF-α has an antimicrobial activity by stimulating the formation of 
granulomas in tuberculosis patients [8]. TNF-α can maintain the state of the dormancy of MTB 
infections in humans, because TNF-α inhibition may decrease the ability to restrict the growth 
of MTB. TNF-α is also shown to directly exert anti-mycobacteria activity in human 
mononuclear phagocytes. 
In this study, the author found a decrease in TNFα levels after intensive phase of 
antituberculosis treatment (p = 0.001). It is in accordance with the research by Kim, et.al. [20] 
stating that there was a decrease in TNFα (p < 0.05) after intensive phases of antituberculosis 
treatment. Research conducted by Mvungi, et.al. in [21] also showed a decrease in TNFα levels 
after intensive phase of antituberculosis treatment. The authors also stated that the decrease in 
the TNFα levels occurred up to 41.5% (p < 0.0001). In addition, there was a decline in other 
cytokine levels such as IFN-γ, IL-6, IL-10, and IL-4 (p < 0.0001). They have also stated that the 
increase and decrease in cytokines can be a predictor in the assessment of the immunological 
response after the antituberculosis therapy, so that in turn can help in providing an overview of 
the progression of the disease and reducing other additional costs that may be required in 
treating these cases which were unresponsive or resistant. 
 The study showed that there was a relationship between the TNFα levels before and 
after intensive phase of antituberculosis treatment in T2DM patients. However, there were some 
limitations in this study. In this study, researchers sought to assess the body mass index, 
however, researchers have not yet listed and conducted assessments of other factors that could 
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influence the body mass index, such as information on body composition, food intake, and else. 
This can be a primarily cofounding factors for cases in which TB patient did not have sufficient 
nutritional intake, so the BMI value changes might be less accurate. In addition, there were 
other infections factors, such as patients with HIV that generally had low BMI. Futhermore, 
there were also various socioeconomic factors that were important and might affect the BMI, in 
which, TB patients were usually associated with low socioeconomics. The improvement of BMI 
in TB and DM patients was also associated with the duration of treatment, meanwhile in this 
study, only includes follow up to intensive phase of treatment. In this study, there was 
conducted assessment of blood sugar levels. There were several factors that can determine blood 
sugar levels, such as physical activity, measurement of blood sugar levels often become 
inaccurate even though in this research in particular also assess the HbA1C level. This research 
has not done the stratification of the severity of TB infection or DM, so that the results obtained 
are still less practical in daily practice. The research also did not consider the treatment being 
taken and the pharmacodynamic interactions between the use of antituberculosis and oral 
hypoglycemic agent or insulin used in this study. 
5. Conclusion 
There was a statistically significant increase of BMI and decrease of TNFα level after intensive 
phase of antituberculosis treatment.  
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